Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review


      Bariatric surgery has emerged as a therapy for obesity and the associated comorbidities. Obesity has been shown to be a risk factor for atrial fibrillation as well as venous thromboembolism, both of which are conditions that warrant anticoagulation. There is significant underrepresentation of the morbidly obese population in prospective trials that evaluated direct oral anticoagulants and vitamin K antagonists in atrial fibrillation and venous thromboembolism. We aim to review all the available data that assessed these oral anticoagulants in the morbidly obese population (body mass index >40 kg/m2 and weight >120 kg) and in the post-bariatric surgery population. Our findings suggest that direct oral anticoagulants may be safe and effective for anticoagulation in morbidly obese patients for both atrial fibrillation and venous thromboembolism. However, warfarin is the preferred agent in the post-bariatric surgery population, given the limited number of studies on direct oral anticoagulants in this population. Further adequately powered randomized control trials are needed to confirm the safety and efficacy of these oral anticoagulants in the morbidly obese and post-bariatric surgery population.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. World Health Organization (WHO). Obesity and overweight. Available at: Accessed March 19, 2021.

        • Buchwald H
        • Estok R
        • Fahrbach K
        • et al.
        Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.
        Am J Med. 2009; 122: 248-256.e5
        • Kearon C
        • Akl EA
        • Ornelas J
        • et al.
        Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.
        Chest. 2016; 149: 315-352
        • Ortel TL
        • Neumann I
        • Ageno W
        • et al.
        American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.
        Blood Adv. 2020; 4: 4693-4738
        • January CT
        • Wann LS
        • Calkins H
        • et al.
        2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: e report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
        Circulation. 2019; 140: e125-e151
        • Martin K
        • Beyer-Westendorf J
        • Davidson BL
        • Huisman MV
        • Sandset PM
        • Moll S
        Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.
        J Thromb Haemost. 2016; 14: 1308-1313
        • Miyasaka Y
        • Barnes ME
        • Gersh BJ
        • et al.
        Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.
        Circulation. 2006; 114: 119-125
        • Lau DH
        • Nattel S
        • Kalman JM
        • Sanders P
        Modifiable risk factors and atrial fibrillation.
        Circulation. 2017; 136: 583-596
        • Abed HS
        • Wittert GA
        • Leong DP
        • et al.
        Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.
        JAMA. 2013; 310: 2050-2060
        • Gami AS
        • Hodge DO
        • Herges RM
        • et al.
        Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation.
        J Am Coll Cardiol. 2007; 49: 565-571
        • Anderson Jr, FA
        • Spencer FA
        Risk factors for venous thromboembolism.
        Circulation. 2003; 107: I9-I16
        • Kunutsor SK
        • Mäkikallio TH
        • Seidu S
        • et al.
        Physical activity and risk of venous thromboembolism: systematic review and meta-analysis of prospective cohort studies.
        Eur J Epidemiol. 2020; 35: 431-442
        • Elshafei MN
        • Mohamed MFH
        • El-Bardissy A
        • et al.
        Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis.
        J Thromb Thrombolysis. 2021; 51: 388-396
        • Spyropoulos AC
        • Ashton V
        • Chen Y-W
        • Wu B
        • Peterson ED
        Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
        Thromb Res. 2019; 182: 159-166
        • Kushnir M
        • Choi Y
        • Eisenberg R
        • et al.
        Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
        Lancet Haemost. 2019; 6: e359-e365
        • Coons JC
        • Albert L
        • Bejjani A
        • Iasella CJ
        Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with acute venous thromboembolism.
        Pharmacotherapy. 2020; 40: 204-210
        • Perales IJ
        • San Agustin K
        • DeAngelo J
        • Campbell AM
        Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight.
        Ann Pharmacother. 2020; 54: 344-350
        • Quan S
        • Smith J
        • Wu C
        • Koshman SL
        • Nguyen B
        • Bungard TJ
        Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism.
        Thromb Res. 2020; 187: 56-62
        • Sa RA
        • Al-Ani F
        • Lazo-Langner A
        • Louzada ML
        Efficacy and safety of direct oral anticoagulants in obese patients with venous thromboembolism.
        Blood. 2019; 134: 3675
        • Kido K
        • Shimizu M
        • Shiga T
        • Hashiguchi M
        Meta-analysis comparing direct oral anticoagulants versus warfarin in morbidly obese patients with atrial fibrillation.
        Am J Cardiol. 2020; 126: 23-28
        • Barakat AF
        • Jain S
        • Masri A
        • et al.
        Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories.
        JACC Clin Electrophysiol. 2021; 7: 649-658
        • Kaplan RM
        • Tanaka Y
        • Passman RS
        • et al.
        Efficacy and safety of direct oral anticoagulants for atrial fibrillation across body mass index categories.
        J Am Heart Assoc. 2020; 9e017383
        • Patil T
        • Lebrecht M
        A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population.
        Thromb Res. 2020; 192: 124-130
        • Hohnloser SH
        • Fudim M
        • Alexander JH
        • et al.
        Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight.
        Circulation. 2019; 139: 2292-2300
        • Kido K
        • Ngorsuraches S
        Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation.
        Ann Pharmacother. 2019; 53: 165-170
        • Peterson ED
        • Ashton V
        • Chen Y-W
        • Wu B
        • Spyropoulos AC
        Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
        Am Heart J. 2019; 212: 113-119
        • Kubitza D
        • Becka M
        • Zuehlsdorf M
        • Mueck W
        Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
        J Clin Pharmacol. 2007; 47: 218-226
        • Mueck W
        • Lensing AWA
        • Agnelli G
        • Décousus H
        • Prandoni P
        • Misselwitz F
        Clin Pharmacokinet. 2011; 50: 675-686
        • Reilly PA
        • Lehr T
        • Haertter S
        • et al.
        The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
        J Am Coll Cardiol. 2014; 63: 321-328
        • Upreti VV
        • Wang J
        • Barrett YC
        • et al.
        Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
        Br J Clin Pharmacol. 2013; 76: 908-916
        • Piran S
        • Traquair H
        • Chan N
        • Bhagirath V
        • Schulman S
        Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study.
        Res Pract Thromb Haemost. 2018; 2: 684-688
        • Tittl L
        • Endig S
        • Marten S
        • Reitter A
        • Beyer-Westendorf I
        • Beyer-Westendorf J
        Impact of BMI on clinical outcomes of NOAC therapy in daily care - results of the prospective Dresden NOAC Registry (NCT01588119).
        Int J Cardiol. 2018; 262: 85-91
        • Martin KA
        • Lee CR
        • Farrell TM
        • Moll S
        Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance.
        Am J Med. 2017; 130: 517-524
        • Kröll D
        • Nett PC
        • Borbély YM
        • et al.
        The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study.
        Surg Obes Relat Dis. 2018; 14: 1890-1896
        • Kröll D
        • Stirnimann G
        • Vogt A
        • et al.
        Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery.
        Br J Clin Pharmacol. 2017; 83: 1466-1475
        • Rottenstreich A
        • Barkai A
        • Arad A
        • Raccah BH
        • Kalish Y
        The effect of bariatric surgery on direct-acting oral anticoagulant drug levels.
        Thromb Res. 2018; 163: 190-195
        • Strong AT
        • Sharma G
        • Nor Hanipah Z
        • et al.
        Adjustments to warfarin dosing after gastric bypass and sleeve gastrectomy.
        Surg Obes Relat Dis. 2018; 14: 700-706
        • Steffen KJ
        • Wonderlich JA
        • Erickson AL
        • Strawsell H
        • Mitchell JE
        • Crosby RD
        Comparison of warfarin dosages and international normalized ratios before and after Roux-en-Y gastric bypass surgery.
        Pharmacotherapy. 2015; 35: 876-880
        • Hendricks AK
        • Zieminski JJ
        • Yao X
        • et al.
        Safety and efficacy of oral anticoagulants for atrial fibrillation in patients after bariatric surgery.
        Am J Cardiol. 2020; 136: 76-80
        • Mahlmann A
        • Gehrisch S
        • Beyer-Westendorf J
        Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.
        J Thromb Thrombolysis. 2013; 36: 533-535
        • Nasser MF
        • Khaled Z
        • Jabri A
        • Karim S
        The importance of use of appropriate anticoagulant in atrial fibrillation after gastric bypass surgery.
        HeartRhythm Case Rep. 2021; 7: 354-356